Soaanz
NDC Package 73502-286-15

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Soaanz is a . Marketed by Sarfez Pharmaceuticals Inc, this product is identified by NDC 73502-286 and is authorized under FDA application NDA213218.

Identification & Billing

NDC Package Code
73502-286-15
Package Description
5 BLISTER PACK in 1 CARTON / 6 TABLET, FILM COATED in 1 BLISTER PACK (73502-286-09)
Product Code
73502-286
11-Digit Billing Format
73502028615

Clinical Specifications

Proprietary Name
Soaanz
Dosage Form
-

Regulatory & Marketing

Labeler Name
Sarfez Pharmaceuticals Inc
FDA Application #
NDA213218
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
01-24-2022
End Marketing Date
01-12-2026
Listing Expiration
01-12-2026
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 73502-286-15 identifies a specific commercial package of 5 blister pack in 1 carton / 6 tablet, film coated in 1 blister pack (73502-286-09) of Soaanz, labeled by Sarfez Pharmaceuticals Inc. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Sarfez Pharmaceuticals Inc on January 24, 2022. The current certification is valid through January 12, 2026.

How is this Sarfez Pharmaceuticals Inc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 73502028615. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
73502-286-15
11-Digit CMS (5-4-2)
73502-0286-15

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.